These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 22370306

  • 1. [Monitoring bone turnover markers during treatment with the anabolic agent teriparatide; in particular, treatment using daily and weekly subucutaneous injections].
    Miyauchi A.
    Clin Calcium; 2012 Mar; 22(3):387-98. PubMed ID: 22370306
    [Abstract] [Full Text] [Related]

  • 2. [Evidence in the treatment of osteoporosis using weekly teriparatide injections].
    Nakamura Y.
    Clin Calcium; 2012 Mar; 22(3):407-13. PubMed ID: 22370308
    [Abstract] [Full Text] [Related]

  • 3. [Relationship of pharmacokinetics, changes of bone turnover markers and BMD/fractures efficacy during treatment with anabolic agents;Teriparatide daily and once weekly subcutaneous injections.].
    Miyauchi A.
    Clin Calcium; 2016 Mar; 26(11):1583-1595. PubMed ID: 27777391
    [Abstract] [Full Text] [Related]

  • 4. [Update and perspectives of anabolic therapies for osteoporosis].
    Endo I, Matsumoto T.
    Clin Calcium; 2012 Mar; 22(3):327-33. PubMed ID: 22370299
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH.
    Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
    [Abstract] [Full Text] [Related]

  • 7. [Effects of parathyroid hormone (teriparatide) on bone quality in osteoporosis].
    Saito M, Marumo K.
    Clin Calcium; 2012 Mar; 22(3):343-55. PubMed ID: 22370301
    [Abstract] [Full Text] [Related]

  • 8. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
    Hashimoto Y, Wakayama N, Miyauchi A.
    Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB.
    J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
    [Abstract] [Full Text] [Related]

  • 11. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
    Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M.
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Once-weekly teriparatide treatment on osteoporosis].
    Nakano T.
    Clin Calcium; 2014 Jan; 24(1):100-5. PubMed ID: 24369286
    [Abstract] [Full Text] [Related]

  • 14. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.
    Cosman F, Nieves J, Woelfert L, Shen V, Lindsay R.
    J Bone Miner Res; 1998 Jun; 13(6):1051-5. PubMed ID: 9626638
    [Abstract] [Full Text] [Related]

  • 15. Effect of dosing frequency of teriparatide (PTH 1-34) on bone formation in rats: comparison of bone metabolism marker levels.
    Watanabe A, Tsurui K, Yoneyama S, Iwata H, Anzai T, Jerome C, Nakae D.
    J Toxicol Sci; 2018 Jun; 43(7):435-442. PubMed ID: 29973475
    [Abstract] [Full Text] [Related]

  • 16. PINP as an aid for monitoring patients treated with teriparatide.
    Tsujimoto M, Chen P, Miyauchi A, Sowa H, Krege JH.
    Bone; 2011 Apr 01; 48(4):798-803. PubMed ID: 21168536
    [Abstract] [Full Text] [Related]

  • 17. Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis.
    Sugimoto T, Nakamura T, Nakamura Y, Isogai Y, Shiraki M.
    Osteoporos Int; 2014 Mar 01; 25(3):1173-80. PubMed ID: 24108429
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U.
    J Assoc Physicians India; 2008 Jun 01; 56():418-24. PubMed ID: 18822620
    [Abstract] [Full Text] [Related]

  • 19. [Effects of parathyroid hormone (teriparatide) on bone mass and quality in osteoporosis].
    Marumo K, Saito M.
    Nihon Rinsho; 2011 Jul 01; 69(7):1264-9. PubMed ID: 21774369
    [Abstract] [Full Text] [Related]

  • 20. [Therapeutic agents for disorders of bone and calcium metabolism: Weekly subcutaneous injection of teriparatide.].
    Ishizuya T.
    Clin Calcium; 2011 Jan 01; 21(1):17-24. PubMed ID: 21187590
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.